Indivior PLC (LON:INDV – Get Free Report)’s stock price dropped 17% on Thursday . The company traded as low as GBX 548.71 ($6.93) and last traded at GBX 720.60 ($9.10). Approximately 2,904,792 shares changed hands during mid-day trading, an increase of 294% from the average daily volume of 737,710 shares. The stock had previously closed at GBX 868 ($10.97).
Wall Street Analyst Weigh In
Separately, Jefferies Financial Group reissued a “buy” rating and set a GBX 1,800 ($22.74) price target on shares of Indivior in a research report on Tuesday, December 17th.
Read Our Latest Research Report on INDV
Indivior Price Performance
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
See Also
- Five stocks we like better than Indivior
- Technology Stocks Explained: Here’s What to Know About Tech
- DuPont’s Electronics Spinoff: The Start of Something Big
- What is a buyback in stocks? A comprehensive guide for investors
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
- What Are Dividends? Buy the Best Dividend Stocks
- Market Shift: These 3 Stocks Are Winning While Big Tech Lags
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.